<i>CFH</i>,<i>VEGF</i>and<i>HTRA1</i>promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration

Abstract

This study reports preliminary evidence suggesting that the higher AMD risk genotypes in CFH, VEGF and HTRA1 may influence the short-term response to treatment with ranibizumab for neovascular AMD.